Introduction
While comparative trials have established tiotropium to be equivalent or superior to LABAs in COPD, 5, 6 studies have demonstrated that when these drugs are used concurrently, there is further significant improvement in lung function and health-related quality of life measures, symptoms scores, rescue medication use, [7] [8] [9] and exercise capacity. 5, 10 These data justify further research in this area, and recent studies have focused on the development of novel once-daily combinations of LABAs and LAMAs in one inhaler. These LAMAs and LABAs potentially offer greater convenience and compliance compared with the use of two separate inhalers.
The When to use combination LABA/LAMA therapy and fixed-dose combination (FDC) LABA/LAMA therapy?
Given the importance of bronchodilation in COPD, national and international guidelines reinforce inhaled bronchodilators as the cornerstone of treatment in all stages of disease severity. FDC inhalers are able to provide extra bronchodilation compared with either monotherapy alone, and are recommended for the use of persistent symptoms despite LABA or LAMA monotherapy (with or without inhaled corticosteroids [ICS] ) (Level B 4 or Level 2 11 evidence for improving forced expiratory volume in 1 second [FEV 1 ] and symptoms). The Global initiative of Obstructive Lung Diseases (GOLD) 4 strategy has been used in major COPD trials to categorize the severity of disease and to guide commencement of LABA or LAMA therapy.
In the GOLD 4 strategy document, patients are divided into four groups (A, B, C, and D) based on FEV 1 , Medical Research Council (MRC) symptoms score, and the frequency of exacerbations in 1 year as follows: A) GOLD 1-2 (ie, FEV 1 $50% predicted), few symptoms MRC ,1, low exacerbation frequency (ie, #1 exacerbation/year and no hospitalization); B) GOLD 1-2, frequent symptoms MRC $2, low exacerbation frequency; C) GOLD 3-4 (ie, FEV 1 ,50% predicted), few symptoms MRC ,1, high exacerbation frequency ($2 exacerbation/year or $1 hospitalization/year); D) GOLD 3-4, frequent symptoms MRC $2, high exacerbation frequency. LABA/LAMA combination therapy is recommended for patients in groups B-D. 4 Group B patients may use either a LABA or LAMA monotherapy, but the combination of a LABA plus a LAMA is presented as an alternative option. Patients in group C are recommended to use either LABA with an ICS or LAMA monotherapy, with alternative options of a LABA plus a LAMA, or a LABA or a LAMA plus a phosphodiesterase-4 (PDE-4) inhibitor. The same drug combinations are recommended for patients in group D. 4 In the Australian COPD guidelines, 11 the rationale to use a FDC bronchodilator in an inhaler-naive patient or to change a patient's current inhaler is based on similar factors to GOLD 4 in conjunction with attention to the complexity of device, patient's preference, and occurrence of adverse events (AEs). 11 The British Thoracic Society guidelines 12 currently recommend the use of combination bronchodilator therapy in cases where the addition of ICS to a bronchodilator is declined or not tolerated. 12 It is also suggested that LAMA plus a LABA should be offered to patients with stable COPD and an FEV 1 .50% who remain breathless or have exacerbations despite maintenance therapy with a LABA. 12 The American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society (ERS) suggest that clinicians may administer combination inhaled therapies (LAMA, LABA, or ICS) for symptomatic patients with stable COPD and FEV 1 ,60% predicted 13 (graded as a weak recommendation with moderate quality evidence to support its use). There is still little evidence to determine the efficacy of FDC LABA/LAMA inhalers on exacerbation rates. This review will focus on the combination of the novel LABA and LAMA, olodaterol with tiotropium bromide and aims to provide an insight in to the pharmacokinetics, pharmacodynamics, the Respimat ® device, as well as the clinical evidence thus far.
Pharmacology

Pharmacokinetics and pharmacodynamics Olodaterol
Olodaterol (Striverdi ® ) is a long-acting, inhaled, β 2 -adrenergic receptor agonist with a 24-hour bronchodilator profile.
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Role of tiotropium/olodaterol in COPD Olodaterol received its first global approval in 2013 for the long-term, once-daily; maintenance bronchodilator treatment of airflow obstruction in patients with COPD in Canada.
14 It has been approved in a number of European countries as a once-daily dose of 5 μg given through a Respimat ® Soft Mist™ inhaler. 15 Olodaterol is a potent and selective agonist of the human β 2 -adrenergic receptor in vitro. 16 Following inhalation, olodaterol binds to and activates β 2 -adrenergic receptors in the airway, stimulating adenyl cyclase to synthesize cyclic 3′5′-adenosine monophosphate, which then leads to smooth-muscle relaxation and bronchodilation. 16 In vitro and in vivo data show that olodaterol potently reverses stimulated bronchi contraction, and reduces pro-fibrotic cellular activity in human lung fibroblast. [16] [17] [18] The half-life of olodaterol is 17.8 hours. 19 In animal studies, olodaterol has demonstrated efficacy over 24 hours. 16 Rapid onset of action with improvement in lung function has been noted within 5 minutes after the first dose in Phase 3 trials in patients with COPD. 20 Ferguson et al 20 more recently established the long-term efficacy and safety of a once-daily olodaterol at 5 μg and 10 μg in patients with GOLD stage 2-4 COPD. This was a two replicate, randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial over 48 weeks. 20 van Noord et al 21 investigated the efficacy of four different doses of olodaterol as a once-daily bronchodilator in a Phase 2 clinical trial, and showed a clear dose-response relationship with significant improvement in FEV 1 from baseline with values ranging between 0.070 L and 0.119 L for at least 24 hours in patients with COPD. 21 In another Phase 2 randomized, double-blind, crossover study, van Noord et al 22 demonstrated a statistically significant increase in lung function (FEV 1 ) outcome for at least 24 hours from baseline. Olodaterol was superior to placebo (P,0.001) in peak FEV 1 (0.121-0.213 L) and a clear dose-response relationship was observed, with values ranging from 0.070 L for olodaterol 2 μg to 0.119 L for olodaterol 20 μg. Overall, the 5 μg dose offered a superior 24-hours profile compared to both the 10 μg daily dose and the twice-daily 2 μg dose. 23 Olodaterol was tolerated at all doses that were tested. There was no relationship of total daily dose to the overall incidence of AEs. 20 Comparatively, Koch et al 24 performed a replicate, multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study investigating the long-term efficacy and safety of once-daily olodaterol via Respimat ® versus placebo and formoterol in patients with moderateto-very-severe COPD. Olodaterol 10 μg was shown to have similar improvement in FEV 1 area under the curve from 0 hour to 3 hours (AUC 0-3 ) and trough FEV 1 to twice-daily formoterol. 24 The 10 μg daily dose did not provide additional improvement compared to the 5 μg daily dose. 24 A recent meta-analysis where 18 trials were identified (eight, olodaterol; ten, indacaterol) evaluating the efficacy of olodaterol and indacaterol in patients with COPD, concluded that both olodaterol and indacaterol had similar efficacy when compared under similar trial conditions. 25 
Tiotropium bromide
Tiotropium bromide (Spiriva ® ) is an anticholinergic bronchodilator, normally administered as a dry powder through a HandiHaler ® device. It is an antagonist of three muscarinic receptor subtypes. 26 Tiotropium demonstrates competitive and reversible receptor antagonism and in vitro studies have shown that tiotropium has a half-life on the M3 receptor of 36 hours.
27 FEV 1 rises slowly following one dose reaching a peak after 1-3 hours and the peak response is followed by a plateau of long duration. 26 van Noord et al 28 found that trough FEV 1 increased by 0.19 L (18%) from initial baseline after 8 days of daily administration. Tiotropium bromide is predominantly a renally excreted drug. 26 Tiotropium bromide has been in the market for at least 15 years and is the first-line long-acting anticholinergic bronchodilator for maintenance therapy in COPD. It has a duration of action of more than 24 hours. 6, 29, 30 It is taken once daily using a HandiHaler ® device and was compared with standard therapy in the four-year Understanding Potential Long-term Impact on Function with Tiotropium (UPLIFT) trial, showing significant improvement in lung function and health status with no evidence of increased cardiovascular risk. 31 It has level A evidence (Supplementary material) for reducing exacerbations and repeated hospitalization as well as improving symptoms and health status, and level B evidence of improving the effectiveness of pulmonary rehabilitation. 4, 32 In two other large trials, tiotropium was superior to salmeterol in reducing exacerbations although the difference was small. 33, 34 More recently, comparisons have been made between tiotropium bromide and the newer individual LAMAs and LABAs as well as their respective FDCs (Table 1) . Indacaterol, a LABA, was approved in 2011 as a maintenance therapy for COPD. The INVIGORATE 35 study compared indacaterol with tiotropium bromide in a randomized, placebo-controlled study involving 3,444 patients with severe COPD. There was no difference in trough FEV 1 36 Glycopyrronium bromide, a LAMA, was compared to tiotropium as well as placebo in the glycopyrronium bromide in COPD airways 2 study (GLOW2) 37 study, which involved 802 patients with moderate-to-severe COPD. Trough FEV 1 , TDI, SGRQ, reducing exacerbation, and rescue medication use was comparable in both groups. 37 More recently, similar findings were also found by Chapman et al 38 where 657 patients with moderate-to-severe COPD were randomized 1:1 to glycopyrronium and tiotropium. 38 The FDC Ultibro ® (glycopyrronium plus indacaterol) has been compared to tiotropium in three different Phase 3 studies, namely SHINE, 39 BLAZE, 40 and SPARK. 41 In SHINE, 39 Ultibro ® improved trough FEV 1 when compared with open-label tiotropium (LSM differences 80 mL; P,0.001 in all comparisons). The dyspnea score for Ultibro ® was also significantly higher than for tiotropium (LSM difference 0.49, 95% CI 0.07-0.91; P=0.021). 39 These results however did not reach clinical significance. The overall rate of mild, moderate, and severe exacerbations was significantly reduced by glycopyrronium plus indacaterol compared with open-label tiotropium (14% reduction, relative risk [RR] 0.86, 95% CI 0.78-0.94, P=0.0017), similar to glycopyrronium alone. While glycopyrronium plus indacaterol also reduced moderate-to-severe exacerbation rates significantly compared with glycopyrronium monotherapy, they were comparable to open-label tiotropium (10% reduction, RR 0.90, 95% CI 0.79-1.02, P=0.096). 41 
Olodaterol and tiotropium bromide
Muscarinic receptors and β 2 -adrenoreceptors are physiological antagonists for smooth-muscle tone in the airway. In the airway, these receptors are expressed at different sites, indicating that the effect of combining β 2 -agonists and muscarinic antagonists results in dilatation across the whole bronchial tree.
9,42-43 β 2 -agonists decrease the release of acetylcholine (ACh), and then amplify the bronchial smooth-muscle relaxation induced by the muscarinic antagonist. Tashkin et al demonstrated that combining bronchodilators with different mechanisms of action might increase the maximum degree of bronchodilation compared to using either drugs alone. 7 Preclinical studies examining the combination of olodaterol and tiotropium bromide found beneficial effects, in particular offering superior bronchoprotection 44, 45 and anti-inflammatory effects. 42 Bouyssou et al examined this FDC tiotropium and olodaterol on ACh-induced bronchoconstriction in anesthetized dogs. Inhalation of 3.0 μg of tiotropium with 6.00 μg of olodaterol (BI 1744) using a Respimat ® Soft Mist™ inhaler connected to the tracheal tube provided dose-dependent protection against ACh-induced bronchoconstriction compared with either monotherapy. 45 There were no relevant cardiovascular effects noted. In another study, Bouyssou et al assessed the synergistic bronchoprotection activity of olodaterol combined with tiotropium bromide and ciclesonide against ovalbumininduced bronchoconstriction in anesthetized guinea pigs. Combining olodaterol with either tiotropium or ciclesonide displayed bronchoprotection in a dose-dependent manner. 
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Drug delivery via Respimat ® Soft Mist™ inhaler
Respimat ® is a fine-mist inhaler delivering the medication independent of inspiratory effort and patient coordination. 46 Respimat ® overcomes some of the limitations of pressurized metered dose inhalers (pMDI), dry powder inhalers, and nebulizers as it is portable, propellant-free, and does not need a spacer/holding chamber. It uses mechanical energy for actuation. Given the small aerosol particle size, it is thought to have more uniform delivery to the smaller airways. 46 In patients with COPD, drug delivery through a Respimat ® was equally effective at a lower dose compared to a drug delivered through a pMDI. 47 It is unclear if device preference leads to improved adherence or clinical outcomes. Schürmann et al 47 showed that 81% preferred the device compared with a pMDI using the patient satisfaction and preference questionnaire, after a 7-week treatment period. 47 There was no difference between inhalers for efficacy measures such as peak expiratory flow, rescue inhaler use, and symptom scores. 46 
Respimat ® device and cardiovascular risk
There have been concerns regarding the safety issues around a Respimat ® device delivering tiotropium. Initially, the Lung Health study 34 indicated that there was increased risk of cardiac deaths in patients using ipratropium bromide, a short-acting antimuscarinic agent. 34 A meta-analysis raised concerns, as it showed an increase in the primary composite end point of cardiovascular death, myocardial infarction, or stroke (RR 1.60, 95% CI 1.22-2.10) and of all-cause mortality (RR 1.29, 95% CI 1.00-1.65). 48 This meta-analysis 48 used 17 studies, 12 of which involved tiotropium bromide delivered by a HandiHaler ® . Understanding Potential Long-term impact on Function with Tiotropium 31 study is a randomized trial of 5,993 patients with COPD, where tiotropium delivered by a HandiHaler ® device was compared to placebo. It concluded that tiotropium was not associated with increased risk of mortality. 31 Another systematic review and meta-analysis of randomized, placebo-controlled trials involving patients using tiotropium delivered by a Respimat ® device in 2011 showed a 50% increased risk of mortality. 49 There was a dose-dependent effect on all-cause mortality. 49 Cardiovascular death was increased with an RR of 2.05 (95% CI 1.06-3.99). 49 Two other independent systematic reviews and meta-analyses have reported a similar significant increased risk of all-cause mortality with tiotropium delivered through a Respimat ® . 50 54 More importantly, the TIOSPIR study showed no difference in mortality between the two delivery systems. This is a well-conducted study and provides more robust evidence than either the meta-analysis or the database study. 53 Recently, Tashkin et al 55 presented an abstract at the ERS Congress, where they pooled data from all randomized, placebo-controlled, double-blind and parallel group clinical trials of tiotropium in COPD of $4 weeks' duration for which they estimated baseline creatinine clearance (Cockcroft-Gault) to provide a safety evaluation of tiotropium in both the HandiHaler ® and Respimat ® . A total of 10,905 patients (15 trials involved tiotropium delivered using a HandiHaler ® and seven trials involved tiotropium delivered via a Respimat ® ) were evaluated and the conclusion was that the incidence of AEs, serious AEs, and fatal AEs with both inhaler devices compared to placebo showed no association with mild-to-moderately-impaired renal function. The database for patients with severe renal impairment is too small to draw any conclusion. 55 However, the questions still remains if tiotropium delivered through the Respimat ® device is safe in patients with a cardiac history or severe renal impairment, as these patient populations were excluded from the TIOSPIR study. 
Clinical efficacy Phase 3 trials
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Muruganandan and Jayaram and for tiotropium added to a fixed dose of olodaterol. 
Clinical efficacy
The TOviTO is a Phase 3 program, 59 which consists of ten studies evaluating the potential benefits and safety profile of the FDC of olodaterol and tiotropium through a Respimat ® Soft Mist™ inhaler. This is the largest Phase 3 trial involving over 8,000 patients with moderate-to-very-severe COPD. It includes two pivotal registration trials NCT01431274 (TOnado 1) 56 and NCT01431287 (TOnado 2), 56 involving over 5,000 patients and assessing lung function, quality of life, and safety.
Lung function and quality of life TOnado 1 56 and TOnado 2 56 are a multicentered, multinational, randomized, double-blind, five-arm, parallel group studies randomizing a total of 5,163 COPD patients across the spectrum of disease severity from GOLD stage 2 to GOLD stage 4 at more than 500 trial sites in approximately 40 countries. They were performed to assess the efficacy and safety of once-daily-inhaled FDC of tiotropium and olodaterol (2.5/5 μg, 5/5 μg) compared with the individual components using the Respimat ® inhaler over 52 weeks. The primary outcome measures were FEV 1 AUC 0-3 response and trough FEV 1 response compared to baseline as well as the SGRQ total score at 24 weeks. Secondary outcomes were Mahler Transition Dyspnea Index focal score at 24 weeks and rescue medication use. There was a significant and clinically relevant improvement in lung function in both FDC of tiotropium and olodaterol doses compared with each monotherapy: with FEV 1 AUC 0-3 improving by over 100 mL. Statistically significant benefits were noted in quality of life and symptom measures with FDC compared with monotherapy, but these did not reach the anticipated minimal clinically important difference. VIVACITO 60 (NCT01559116), the third study within the TOviTO program, is a 6-week randomized, doubleblind, crossover trial aimed at characterizing the 24-hour lung function profiles of tiotropium and olodaterol FDC at two different doses (2.5/5 μg, 5/5 μg) compared with monotherapy and placebo. All medications were delivered by the Respimat ® Soft Mist™ inhaler. The primary endpoint FEV 1 AUC 0-24 response at week 6 improved significantly at both doses of FDC compared with tiotropium (mean treatment difference of 110-127 mL, P,0.0001) or olodaterol (mean treatment difference of 115 mL, P,0.0001), monotherapies, or with placebo (mean treatment difference of 280 mL, P,0.0001). Both doses of the tiotropium and olodaterol FDC showed similar lung function profiles with an increase of 200 mL in trough FEV 1 compared with placebo. 60 
ENERGITO
61 (NCT01969721), the fourth study in the TOviTO program, is intended to provide evidence of superior improvements in lung function with high-and low-dose FDC of tiotropium and olodaterol (FDC1.25/2.5 μg and 2.5/2.5 μg) compared with high and low dose FDC of fluticasone pro pionate and salmeterol (Accuhaler ® 250/50 μg and 500/50 μg) in 228 COPD patients. In this four-period crossover trial, patients will undergo pulmonary function tests at regular intervals for 24 hours at the end of each 6-week treatment period. The primary outcome is change from baseline in FEV 1 AUC 0-12 . This study is currently recruiting patients and is due to complete in January 2015. PHYSACTO 67 (NCT02085161), the tenth trial in the TOviTO program, is a 12-week randomized, placebo, parallel group study examining the efficacy of FDC tiotropium and olodaterol compared with monotherapy (T/O 5/5 μg, T 5 μg; O 5 μg; placebo), exercise capacity, and physical activity in addition to supervised exercise training and behavior modification in 300 patients. The Endurance Shuttle Walk Test assesses exercise capacity, the primary outcome, at 8 weeks. Secondary outcome measures include daily walking intensity measured with an activity monitor and lung function. This trial is currently recruiting participants.
A trial assessing the efficacy of FDC tiotropium and olodaterol on exacerbations and survival, DYNAGITO 68 (NCTO2296138), has started recruiting patients as of January 2015.
Safety
TOnado 1 56 and 2 56 are randomized trials, which were performed to assess safety of the FDC of olodaterol and tiotropium being delivered via the Respimat ® Soft Mist™ inhaler. Pooled safety results over the 52-week period were reported in 5,163 patients. Incidence of AEs was generally balanced across all treatment groups with the majority being mild-to-moderate in severity. Overall, 6.4% of AEs were considered treatment-related. The rates of serious AEs and fatalities were similar across treatment arms.
Cardiovascular side effects, in particular prolonged QT, occurred in a dose-dependent manner. In healthy volunteers, the upper limit of the 90% CI of the placebo adjusted change from baseline was below 10 ms with olodaterol 10 μg. Patients taking tiotropium had a 30-60-ms change in the corrected QT (QTc) interval. No patients had a QTc interval of .500 ms, and this finding was not replicated in any of the other studies. 
Discussion
FDC LABA/LAMA therapy is expected to become part of the pharmacological armamentarium in the management of COPD with the recent availability of several new oncedaily LABA and muscarinic antagonists and their associated promise of improved efficacy and compliance. Studies to date have demonstrated that combining olodaterol combined with tiotropium delivered via the Respimat ® Soft Mist™ device, improves lung function, dyspnea, and quality of life measures significantly compared with its mono components alone in patients with GOLD stage 2-4 COPD. These agents however have not demonstrated additional clinical benefit to existing individual LABAs and LAMAs used concurrently. 11 The current consensus from the Thoracic Society of Australia and New Zealand suggests that FDCs have a role as add-on therapy in improving symptomatic breathlessness: they provide an effective, convenient, and potentially safer alternative to a LABA/ICS combination in step up therapy in symptomatic patients on regular LAMA, reducing the overuse of ICS in this group.
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Once-daily medication is anticipated to increase compliance with inhaler therapy, a documented problem in patients with COPD. The use of a single, long-acting inhaler is reportedly associated with higher treatment persistence and adherence rates when compared with multiple longacting inhaler use. 69 With the advent of several new FDC long-acting once-daily LAMA/LABA combinations such as vilanterol/umeclidinium and indacaterol/glycopyrronium, the unique role of each combination including olodaterol/ tiotropium needs to be determined. The diversity of the duration and rapid onset of action provided by these new agents may encourage the practice of personalized medicine where choices are guided by patient preference to drug and device, as well as phenotypic features (eg, breathlessness, non-eosinophilic airway inflammation).
The inhalational device used to deliver the FDC of olodaterol and tiotropium is a novel approach and overcomes some of the limitations of pMDI, such as hand-breath coordination and generation of high inspiratory flow. 70 Currently, the evidence is inconclusive about the dangers of Respimat ® delivering tiotropium. Meta-analyses and epidemiological studies comparing the tiotropium delivered via the Respimat ® device with the HandiHaler ® have raised the concern of an increased risk of cardiovascular events. [48] [49] [50] [51] This has been disproven in a large, well-designed and well-conducted prospective study (TIOSPIR) examining safety as its primary end point. 53 The hypothesis that these findings may be due to an anticholinergic class effect remains to be tested.
Published safety data to date with FDC olodaterol/ tiotropium in Phase 2 and 3 studies have shown no significant increased side effects compared with placebo. In conjunction with the increasing choice in FDC LABA/LAMA medications delivered by alternative devices, there may be a reluctance to use the Respimat ® device until further data are available.
Large head-to-head comparisons among the new long FDC LABA/LAMA assessing the efficacy and safety profile with respect to cardiovascular outcomes are required. The benefits may lie in specific points of difference and reassurance of the FDC's safety profile.
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